This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Leeuwen, E.
Right arrow Articles by Prins, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Leeuwen, E.
Right arrow Articles by Prins, J. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2007, p. 335-337, Vol. 51, No. 1
0066-4804/07/$08.00+0     doi:10.1128/AAC.00774-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Penetration of Atazanavir in Seminal Plasma of Men Infected with Human Immunodeficiency Virus Type 1{triangledown}

E. van Leeuwen,1,2* R. ter Heine,3 F. van der Veen,1 S. Repping,1 J. H. Beijnen,3 and J. M. Prins2

Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Academic Medical Center, Amsterdam,1 Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, and Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, Amsterdam,2 Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands3

Received 27 June 2006/ Returned for modification 24 July 2006/ Accepted 19 October 2006

In this exploratory study, the human immunodeficiency virus (HIV) protease inhibitor atazanavir was detected in seminal plasma in 15 out of 15 HIV-infected men taking an atazanavir-containing regimen. However, this penetration was limited and variable, and the median seminal/blood plasma ratio was only 0.1.

* Corresponding author. Mailing address: Academic Medical Centre, Obstetrics and Gynecology, H4-205, Meibergdreef 9, 1100 DD Amsterdam, The Netherlands. Phone: 31205663753. Fax: 31206963489. E-mail: e.vanleeuwen{at}amc.uva.nl.

{triangledown} Published ahead of print on 30 October 2006.

Antimicrobial Agents and Chemotherapy, January 2007, p. 335-337, Vol. 51, No. 1
0066-4804/07/$08.00+0     doi:10.1128/AAC.00774-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Dinoso, J. B., Kim, S. Y., Wiegand, A. M., Palmer, S. E., Gange, S. J., Cranmer, L., O'Shea, A., Callender, M., Spivak, A., Brennan, T., Kearney, M. F., Proschan, M. A., Mican, J. M., Rehm, C. A., Coffin, J. M., Mellors, J. W., Siliciano, R. F., Maldarelli, F. (2009). Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 106: 9403-9408 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»